Fundz

Syremis Therapeutics secures $165M Series A funding co-led by Dexcel Pharma and Third Rock Ventures to develop innovative medicines for mental health.

PRIVATEDec 18, 2025

Amount Raised

$165 Million

Round Type

Series A

Tel AvivBiotechnologyHealth Care

Investors

Third Rock VenturesBain Capital Life SciencesGVQvtPictetDexcel Pharma

Description

Syremis Therapeutics has launched with a $165 million financing to develop treatments for mental health conditions. The Series A funding will support the advancement of their clinical pipeline. Syremis' lead program is currently in Phase 1 for schizophrenia and is designed to potentially offer better treatment options. This financing aims to address a significant unmet need in mental health care.

Who to call at Syremis Therapeutics, and when

A new round usually means Syremis Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Syremis Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Syremis Therapeutics, from your own LinkedIn network
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Syremis Therapeutics

Location

Tel Aviv, Tel Aviv District, Israel

About

Syremis Therapeutics is a clinical-stage biopharmaceutical company developing novel medicines to make a profound impact on the treatment of mental health. The company’s neuropsychiatric pipeline is rooted in emerging and clinically validated mechanisms, including muscarinic M1/M4 agonism and next-generation NMDA antagonism.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Syremis Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for Syremis Therapeutics's next move

See what Strategic adds

Funding Insights

What this usually means
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months

Syremis Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.